3-(4-chlorophenyl)-6-ethoxycarbonyl-1,3,5-triazabicyclo[3.1.0]hexane-2,4-dione | 119020-76-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(4-chlorophenyl)-6-ethoxycarbonyl-1,3,5-triazabicyclo[3.1.0]hexane-2,4-dione
• 英文别名: Ethyl 3-(4-chlorophenyl)-2,4-dioxo-1,3,5-triazabicyclo[3.1.0]hexane-6-carboxylate
• CAS: 119020-76-7
• 化学式: C₁₂H₁₀ClN₃O₄
• 分子量: 295.682
• InChiKey: AQDQPBXPJCDIMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-6-ethoxycarbonyl-1,3,5-triazabicyclo[3.1.0]hexane-2,4-dione 以2%的产率得到
  参考文献：
  名称：

  IZYDORE, ROBERT A.;CHAPMAN, JOHN J.;MITCHELL, JOHN A.;CUMMINGS, ROBERT;JO+, J. CHEM. SOC. PERKIN TRANS. PT 2,(1988) N 8, C. 1415-1422

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(4-chlorophenyl)-1,2,4-triazoline-3,5-dione 、 重氮乙酸乙酯 以 二氯甲烷 为溶剂， 以95%的产率得到3-(4-chlorophenyl)-6-ethoxycarbonyl-1,3,5-triazabicyclo[3.1.0]hexane-2,4-dione
  参考文献：
  名称：

  Izydore, Robert A.; Chapman, John J.; Mitchell, John A., Journal of the Chemical Society. Perkin transactions II, 1988, p. 1415 - 1422

  摘要：

  DOI：

文献信息

• Method for control of hyperlipidemia
  申请人：——

  公开号：US04866058A1

  公开（公告）日：1989-09-12

  The present invention is directed to a method of controlling hyperlipidemia in mammals which comprises administering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: ##STR1## wherein R.sup.1 is hydrogen, a C.sub.1 to C.sub.18 alkyl or substituted alkyl, a C.sub.2 to C.sub.18 alkenyl or substituted alkenyl, a C.sub.2 to C.sub.18 alkynyl or substituted alkynyl, a C.sub.4 to C.sub.10 cycloalkyl or substituted cycloalkyl, a C.sub.4 to C.sub.10 cycloalkenyl or substituted cycloalkenyl, phenyl, a substituted phenyl, cyano, phenalkyl, --CO--R.sup.9 or --Y--CO--R.sup.9 ; R.sup.2 is ##STR2## R.sup.3 and R.sup.4 can be the same or different and are each the same as R.sup.1 ; R.sup.5, R.sup.6 and R.sup.7 can be the same or different and are each hydrogen, a C.sub.1 to C.sub.18 alkyl or substituted alkyl, a C.sub.2 to C.sub.18 alkenyl or substituted alkenyl, a C.sub.1 to C.sub.18 alkynyl or substituted alkynyl, a C.sub.4 to C.sub.10 cycloalkyl or substituted cycloalkyl, a C.sub.4 to C.sub.10 cycloalkenyl or substituted cycloalkenyl, phenyl or substituted phenyl, phenalkyl, --CO--R.sup.9, or --Y--CO--R.sup.9, with the proviso that R.sup.5 and R.sup.6 together cannot be so bulky as to cause the compound to decompose; R.sup.8 is hydrogen, a C.sub.1 to C.sub.5 alkyl, a C.sub.4 to C.sub.10 cycloalkyl, --CO--R.sup.9 or Y--CO--R.sup.9 ; R.sup.9 is hydrogen, a C.sub.1 to C.sub.5 alkyl or substituted alkyl, a C.sub.2 to C.sub.5 alkenyl or substituted alkenyl, a C.sub.2 to C.sub.5 alkynyl or substituted alkynyl, phenyl or substituted phenyl, phenoxy or substituted phenoxy, a C.sub.1 to C.sub.5 alkoxy or substituted alkoxy, a C.sub.4 to C.sub.10 cycloalkyl or substituted cycloalkyl, a C.sub.4 to C.sub.10 cycloalkenyl or substituted cycloalkenyl, --NHC.sub.6 C.sub.5l , --NR.sup.10 R.sup.11 wherein R.sup.10 and R.sup.11 can be the same or different and are each hydrogen, a C.sub.1 to C.sub.5 alkyl or substituted alkyl, phenyl or substituted phenyl; Y is a C.sub.1 to C.sub.10 alkylene or substituted alkylene; R.sup.12 is --CO, --COH, --CS, --CSH, or a C.sub.1 to C.sub.4 alkylene group; and and the pharmaceutically acceptable salts, and mixtures thereof.

  本发明涉及一种控制哺乳动物高脂血症的方法，包括向哺乳动物施用具有降脂活性和结构式的化合物的有效量以控制高脂血症：其中R.sup.1是氢，C.sub.1到C.sub.18烷基或取代烷基，C.sub.2到C.sub.18烯基或取代烯基，C.sub.2到C.sub.18炔基或取代炔基，C.sub.4到C.sub.10环烷基或取代环烷基，C.sub.4到C.sub.10环烯基或取代环烯基，苯基，取代苯基，氰基，苯基烷基，--CO--R.sup.9或--Y--CO--R.sup.9；R.sup.2是；R.sup.3和R.sup.4可以相同也可以不同，且每个都与R.sup.1相同；R.sup.5、R.sup.6和R.sup.7可以相同也可以不同，且每个是氢，C.sub.1到C.sub.18烷基或取代烷基，C.sub.2到C.sub.18烯基或取代烯基，C.sub.1到C.sub.18炔基或取代炔基，C.sub.4到C.sub.10环烷基或取代环烷基，C.sub.4到C.sub.10环烯基或取代环烯基，苯基或取代苯基，苯基烷基，--CO--R.sup.9或--Y--CO--R.sup.9，但R.sup.5和R.sup.6在一起不能太大以致使化合物分解；R.sup.8是氢，C.sub.1到C.sub.5烷基，C.sub.4到C.sub.10环烷基，--CO--R.sup.9或Y--CO--R.sup.9；R.sup.9是氢，C.sub.1到C.sub.5烷基或取代烷基，C.sub.2到C.sub.5烯基或取代烯基，C.sub.2到C.sub.5炔基或取代炔基，苯基或取代苯基，苯氧基或取代苯氧基，C.sub.1到C.sub.5烷氧基或取代烷氧基，C.sub.4到C.sub.10环烷基或取代环烷基，C.sub.4到C.sub.10环烯基或取代环烯基，--NHC.sub.6C.sub.5l，--NR.sup.10R.sup.11其中R.sup.10和R.sup.11可以相同也可以不同，且每个是氢，C.sub.1到C.sub.5烷基或取代烷基，苯基或取代苯基；Y是C.sub.1到C.sub.10烷基或取代烷基；R.sup.12是--CO，--COH，--CS，--CSH或C.sub.1到C.sub.4烷基基团；以及药学上可接受的盐和混合物。
• US4866058A
  申请人：——

  公开号：US4866058A

  公开（公告）日：1989-09-12
• US5034528A
  申请人：——

  公开号：US5034528A

  公开（公告）日：1991-07-23
• US5192761A
  申请人：——

  公开号：US5192761A

  公开（公告）日：1993-03-09
• [EN] METHOD FOR THE CONTROL OF HYPERLIPIDEMIA
  申请人：UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：WO1990000897A1

  公开（公告）日：1990-02-08

  (EN) The invention provides pharmaceutical compositions comprising hypolipidemically active derivatives of 1,2,4-triazolidine-3,5-diones, 1,3,5-triazabicyclo[3.1.0]hexane-2,4-diones, and 1,3,5-triazine-2,4(1H,3H)-diones in a pharmaceutically acceptable carrier for treating hyperlipidemia in mammals, particularly humans. The present invention is also directed to a method of controlling hyperlipidemia in mammals which comprises administering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and structural formula (I), wherein R1 is hydrogen, a C1 to C18 alkyl or substituted alkyl, a C2 to C18 alkenyl or substituted alkenyl, a C2 to C18 alkynyl or substituted alkynyl, a C4 to C10 cycloalkyl or substituted cycloalkyl, a C4 to C10 cycloalkenyl or substituted cycloalkenyl, phenyl, a substituted phenyl, cyano, phenalkyl, -CO-R9 or -Y-CO-R9; R2 is (a), (b), (c), R3 and R4 can be the same or different and are each the same as R1; R5, R6 and R7 can be the same or different and are each hydrogen, a C1 to C18 alkyl or substituted alkyl, a C2 to C18 alkenyl or substituted alkenyl, a C1 to C18 alkynyl or substituted alkynyl, a C4 to C10 cycloalkyl or substituted cycloalkyl, a C4 to C10 cycloalkenyl or substituted cycloalkenyl, phenyl or substituted phenyl, phenalkyl, -CO-R9, or -Y-CO-R9, with the proviso that R5 and R6 together cannot be so bulky as to cause the compound to decompose; R8 is hydrogen, a C1 to C5 alkyl, a C4 to C10 cycloalkyl, -CO-R9, or -Y-CO-R9; R9 is hydrogen, a C1 to C5 alkyl or substituted alkyl, a C2 to C5 alkenyl or substituted alkenyl, a C2 to C5 alkynyl or substituted alkynyl, phenyl or substituted phenyl, phenoxy or substituted phenoxy, a C1 to C5 alkoxy or substituted alkoxy, a C4 to C10 cycloalkyl or substituted cycloalkyl, a C4 to C10 cycloalkenyl or substituted cycloalkenyl, -NHC6C5, -NR10R11 wherein R10 and R11 can be the same or different and are each hydrogen, a C1 to C5 alkyl or substituted alkyl, phenyl or substituted phenyl; Y is a C1 to C10 alkylene or substituted alkylene; R12 is -CO, -COH, -CS, -CSH, or a C1 to C4 alkylene group; and the pharmaceutically acceptable salts, and mixtures thereof.(FR) Compositions pharmaceutiques comprenant des dérivés hypolipidémiants de 1,2,4-triazolidine-3,5-diones, 1,3,5-triazabicyclo[3.1.0]hexane-2,4-diones, et 1,3,5-triazine-2,4(1$i(H),3$i(H))-diones dans un véhicule pharmaceutiquement acceptable pour le traitement de l'hyperlipidémie chez les mammifères, en particulier chez l'homme. La présente invention porte également sur une méthode pour enrayer l'hyperlipidémie chez les mammifères, consistant à administrer à un mammifère une quantité, suffisante pour enrayer l'hyperlipidémie, d'un composé hypolipidémiant selon la formule développée (I), où R1 est hydrogène, un alkyle ou alkyle susbstitué C1 à C18, un alkényle ou alkényle substitué C2 à C18, un alkynyle ou alkynyle substitué C2 à C18, un cycloalkyle ou cycloalkyle substitué C4 à C10, un cycloalkényle ou cycloalkényle substitué C4 à C10, phényle, un phényle substitué, cyano, phénylalkyle, -CO-R9 ou -Y-CO-R9; R2 est (a), (b), (c); R3 et R4 peuvent être identiques ou différents et représentent chacun la même chose que R1; R5, R6 et R7 peuvent être identiques ou différents et représentent chacun hydrogène, un alkyle ou alkyle substitué C1 à C18, un alkényle ou alkényle substitué C2 à C18, un alkynyle ou alkynyle substitué C1 à C18, un cycloalkyle ou cycloalkyle substitué C4 à C10, un cycloaklényle ou cycloalkényle substitué C4 à C10, phényle ou phényle substitué, phénylalkyle, -CO-R9 ou -Y-CO-R9, à la condition que R5 et R6 ne soient, ensemble, pas assez volumineux pour provoquer la décomposition du composé; R8 est hydrogène, un alkyle C1 à C5, un cycloalkyle C4 à C10, -CO-R9 ou -Y-CO-R9; R9 est hydrogène, un alkyle ou alkyle substitué C1 à C5, un alkényle ou alkényle substitué C2 à C5, un alkynyle ou alkynyle substitué C2 à C5, phényle ou phényle substitué, phénoxy ou phénoxy substitué, un alkoxy ou alkoxy substitué C1 à C5, un cycloalkyle ou cycloalkyle substitué C4 à C10, un cycloalkényle ou cycloalkényle substitué C4 à C10, -NHC6C5, -NR10R11, où R10 et R11 peuvent être identiques et différents et représentent chacun hydrogène, un alkyle ou alkyle substitué C1 à C5, phényle ou phényle substitué; Y est un alkylène ou alkylène substitué C1 à C10; R12 est -CO, -COH, -CS, -CSH ou un groupe alkylène C1 à C4; et les sels et mélanges pharmaceutiquement acceptables dudit composé.